Ascorbic Acid

Ascorbic Acid

SCHEMBL6937259

O=C1O[C@H]([C@@H](O)CO)C(O)=C1O.Oc1ccc(O)cc1

nearest known ligand 0.83

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.83
LMNA P02545 2/20 0.83
L3MBTL1 Q9Y468 1/20 0.83
TYR P14679 2/20 0.55
HSPD1 P10809 1/20 0.46
HSPE1 P61604 1/20 0.46
TST Q16762 1/20 0.46
RECQL P46063 1/20 0.46
BLM P54132 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
MANBA O00462 1/20 0.34
THRB P10828 1/20 0.34
HIF1A Q16665 1/20 0.34
PTPN1 P18031 1/20 0.31
CDC25A P30304 1/20 0.31
CDC25B P30305 1/20 0.31
CDC25C P30307 1/20 0.31
DUSP3 P51452 1/20 0.31
CA1 P00915 1/20 0.30
CA3 P07451 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ascorbic Acid SCHEMBL5033864 0.94 MAPT (0.78) MAPTLMNAL3MBTL1TYRHSPD1
Ascorbic Acid SCHEMBL30461160 0.93 MAPT (0.96) MAPTLMNAL3MBTL1TYRHSPD1
Ascorbic Acid SCHEMBL734589 0.91 MAPT (1.00) MAPTLMNAL3MBTL1TYRHSPD1
Ascorbic Acid SCHEMBL2564750 0.91 MAPT (1.00) MAPTLMNAL3MBTL1TYRHSPD1
Ascorbic Acid SCHEMBL785 0.91 MAPT (1.00) MAPTLMNAL3MBTL1TYRHSPD1
Ascorbic Acid SCHEMBL786 0.91 MAPT (1.00) MAPTLMNAL3MBTL1TYRHSPD1
Ascorbic Acid SCHEMBL10957988 0.91 MAPT (1.00) MAPTLMNAL3MBTL1TYRHSPD1
Ascorbic Acid SCHEMBL11981759 0.91 MAPT (1.00) MAPTLMNAL3MBTL1TYRHSPD1
Ascorbic Acid SCHEMBL21114349 0.91 MAPT (1.00) MAPTLMNAL3MBTL1TYRHSPD1
Ascorbic Acid SCHEMBL18678 0.91 MAPT (1.00) MAPTLMNAL3MBTL1TYRHSPD1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030198657-A1 Methods using phytol to improve the appearance of skin and compositions for such methods AVON PRODUCTS, INC. 2003-10-23 US disclosed
EP-1261314-A4 METHODS USING PHYTOL TO IMPROVE THE APPEARANCE OF SKIN AND COMPOSITIONS FOR SUCH METHODS AVON PROD INC (US) 2003-06-11 EP disclosed
EP-1261314-A1 METHODS USING PHYTOL TO IMPROVE THE APPEARANCE OF SKIN AND COMPOSITIONS FOR SUCH METHODS AVON PRODUCTS, INC. (US) 2002-12-04 EP disclosed
WO-2001066080-A1 METHODS USING PHYTOL TO IMPROVE THE APPEARANCE OF SKIN AND COMPOSITIONS FOR SUCH METHODS AVON PRODUCTS, INC. (US) 2001-09-13 WO disclosed
US-4803991-A Three electrode hydroquinone subcutaneous equilibrating tonometer BAXTER HEALTHCARE CORPORATION (US) 1989-02-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030198657-A1 Methods using phytol to improve the appearance of skin and compositions for such methods CUTA, RARA, RXRA MAPT 3738/4885LMNA 368/4885L3MBTL1 3720/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.